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Background
For patients on treatment with HIV RNA <50 copies/
mL, it is unknown whether the genetic barrier to evolu-
tion of resistance is different for DRV/r monotherapy,
compared with standard triple combinations of antire-
trovirals. Several minor IAS-USA mutations are detected
frequently in samples from PI naïve patients.
Methods
In the MONET trial, 256 patients with no history of viro-
logical failure and HIV RNA <50 copies/mL on current
HAART (NNRTI based (43%), or PI based (57%) switched
to either DRV/r monotherapy (800/100 mg OD) versus
DRV/r + 2NRTIs. HIV RNA levels were evaluated at
Weeks 2, 12, 24, 36, 48, 60, 72, 84 and 96: all patient sam-
ples with HIV RNA above 50 copies/mL were sent for
genotypic resistance analysis (VircoTYPE HIV-1, Beerse,
Belgium). Virtual phenotype was also assessed when PI
mutations were detected. The percentage of patients with
major or minor IAS-USA PI mutations was analysed by
treatment arm.
Results
Patients were 81% male and 91% Caucasian, with med-
ian age 43 years, and median CD4 count of 575 cells/
uL. While patients were receiving randomised treatment,
HIV RNA was above 50 copies/mL for 47/1051 (4.5%)
patient-visits in the DRV/r + 2NRTI arm and 69/1009
(6.8%) patient-visits in the DRV/r monotherapy arm. Of
48 patients with at least one successful genotype (27 in
the DRV/r monotherapy arm, 21 in the DRV/r + 2NRTI
arm), two showed major IAS-USA PI mutations during
short-term elevations in HIV RNA (one per treatment
arm). Both patients remained phenotypically sensitive to
darunavir, with sustained HIV RNA<50 copies/mL dur-
ing the trial and no change in antiretroviral treatment.
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detected in the DRV/r mono and DRV/r + 2NRTI arms
were L63P (78%, 62% respectively), I93L (59%, 19%),
V77I (33%, 43%), I62V (22%, 33%) and I64V (15%, 24%).
These five mutations were also commonly observed in
the Stanford HIV database of 7601 samples from PI
naive patients. Fourteen patients in the DRV/r mono-
therapy arm had repeated genotypes during intermittent
low-level viraemia — there was no evidence for evolu-
tion of minor IAS-USA PI mutations over time in these
patients.
Conclusions
After 96 weeks of treatment in the MONET trial, there
is no evidence for an increased risk of emergence of
major or minor IAS-USA PI mutations with DRV/r
monotherapy, compared to DRV/r + 2 NRTIs, and no
evidence for evolution of PI mutations after repeated
genotyping.
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